PALO ALTO, Calif., March 31, 2020 /PRNewswire/ --
Highlights
- RapidPlan PT is the first clinical application of machine
learning in proton treatment planning
- RT Peer Review is designed to streamline and accelerate the
radiation therapy peer review process
- Eclipse v16 has received CE mark and is 510(k) pending
Driven by its Intelligent Cancer Care approach in developing new
solutions that use advanced technologies like machine learning,
Varian (NYSE: VAR), today announced the newest release of its
treatment planning system, Eclipse™ v16. This new release includes
intelligent features such as RapidPlan® PT, the first
clinical application of machine learning in proton treatment
planning, and RT Peer Review, which is a collaborative workspace
designed to streamline and accelerate the peer review process for
radiotherapy treatment plans.
Previously only available for photon-based radiotherapy
treatment planning, RapidPlan is knowledge-based treatment planning
software that enables clinicians to leverage knowledge and data
from similar prior treatment plans to quickly develop high-quality
personalized plans for patients. This knowledge-based
planning software is now available for proton treatment planning
with RapidPlan PT. The software also allows dose prediction
with machine learning models that can be used as a decision support
tool to determine which patients would be appropriate for proton or
photon therapy. Varian is the first vendor in the industry to offer
machine learning capability in both proton and photon treatment
planning.
"With the number of operational proton treatment rooms
continuing to increase, there is a need for experienced proton
therapy clinicians," said Kolleen
Kennedy, chief growth officer, president, Proton Solutions,
Varian. "RapidPlan PT helps bridge the learning curve, allowing
established centers to share their models and clinical experience.
The machine learning in RapidPlan PT has the potential to reduce
proton treatment plan optimization from a one to eight hour
process, as reported by clinical proton centers, to less than 10
minutes, while also potentially improving plan quality."
In many radiotherapy departments, radiation therapy peer review
meetings have been routinely integrated into the clinical QA
process for safer healthcare delivery for the patient.
Although the relevant patient information is manually retrievable
from the clinical database, there is currently no efficient and
effective platform to support these peer reviews. The RT Peer
Review feature in Eclipse v16 is designed for the oncology
community to seamlessly integrate this review process into their
normal clinical workflow by automatically presenting the necessary
information that is required for peer review.
Eclipse v16 has received the CE mark and is 510(k) pending. For
more information on Eclipse v16, visit www.varian.com/eclipse.
About Varian
At Varian, we envision a world without
fear of cancer. For more than 70 years, we have developed, built
and delivered innovative cancer care technologies and solutions for
our clinical partners around the globe to help them treat millions
of patients each year. With an Intelligent Cancer Care approach, we
are harnessing advanced technologies like artificial intelligence,
machine learning and data analytics to enhance cancer treatment and
expand access to care. Our 10,000 employees across 70 locations
keep the patient and our clinical partners at the center of our
thinking as we power new victories in cancer care. Because, for
cancer patients everywhere, their fight is our fight. For more
information, visit http://www.varian.com and follow
@VarianMedSys on Twitter.
Press Contact
Rosemarie Smith-Wood
Sr. Director, Global Brand and Marketing
+1 (650) 424-5208
rosemarie.smith-wood@varian.com
Investor Relations Contact
Anshul Maheshwari
Vice President, Investor Relations
+1 (650) 424-5631
investors@varian.com
View original
content:http://www.prnewswire.com/news-releases/varian-brings-machine-learning-to-proton-treatment-planning-with-eclipse-v16-301032290.html
SOURCE Varian